Oseltamivir
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Antivirals | Oseltamivir | Treatment: 75mg PO QHD x 5 days; prophylaxis: 30mg PO Q24H on day 1, then 30mg PO QHD | Administer Post-HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 312 | 99 | 6-10 | >20 | 3 | 0.3-0.4 | 111-196 | 53-70 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Dolley-Hitze T, Verdier M, Tribut O, Le Tulzo Y, Marqué S. Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis. Intensive care medicine 2010; 36(9), 1618-9.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00198
- Influenza P, Characteristics P, Widmer N et al. Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. Clinical Pharmacokinetics 2010; 49(11), 741-765.
- Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2006; 21(9), 2556-62.
- Stompór T, Krzanowski M, Kusnierz-Cabala B et al. Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2006; 21(12), 3605-6; author reply 3606.